The site offers advanced intermediate and API manufacturing from preclinical stages to commercial manufacturing. The 169-acre site is designed to manufacture a range of synthetic molecules, including small molecules, high potency APIs, and related conjugates.
The phase I of the site (84 acres) has started operation. It has 9 plants with a total reactor volume exceeding 1,000 m³.
In 2025 and beyond, with more plants in operation, our total reactor volume will exceed 4,000 m³.
